Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TFF2
REST API REST API
Homo sapiens
TFF2 is differentially expressed in 153 experiments: 54 organism parts: liver, ovary, ... (52 more);, 61 disease states: normal, gastric carcinoma, ... (59 more);, 36 cell types 161 cell lines 13 compound treatments and 52 other conditions.
Synonyms SML1
Orthologs Tff2 (Mus musculus)   ENSGALG00000016165 (Gallus gallus)   A4FUH6_BOVIN (Bos taurus)   Tff2 (Rattus norvegicus)   tff2 (Xenopus laevis)   TFF2_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term digestion, extracellular region
InterPro Term P_trefoil, P_trefoil_chordata
UniProt Accession Q03403
Search EB-eye ENSG00000160181
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-803, E-GEOD-2361, E-MTAB-24, ... (18 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (28 experiments)

Factor Value U/D Experiments
DU145
2
 E-GEOD-17482, E-GEOD-20089
LNCaP
2
 E-GEOD-14990, E-GEOD-14464
MDA-MB-231
2
 E-TABM-420, E-MTAB-62
SW480
2
 E-MEXP-1014, E-GEOD-18005
primary culture
2
 E-GEOD-2450, E-GEOD-1657
PC3
1
2
 E-GEOD-5258, E-MEXP-2034, E-GEOD-14464
155 more value(s).


Cell type

studied in E-GEOD-15893, E-GEOD-10797, E-GEOD-18811, E-AFMX-5, E-MEXP-1121, ... (21 experiments)

Factor Value U/D Experiments
white blood cell
1
 E-GEOD-2006
erythropoietic
1
 E-GEOD-9894
BDCA4+ dentritic cell
1
 E-TABM-145
testis - leydig cell
1
 E-AFMX-5
CD56+ NK cells
1
1
 E-AFMX-5
adipocyte
1
 E-AFMX-5
30 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-19743, E-GEOD-2466, E-GEOD-3365, E-MEXP-2069, ... (21 experiments)

Factor Value U/D Experiments
prostate carcinoma
2
 E-MTAB-62, E-MEXP-2034
gastric carcinoma
1
2
 E-MTAB-37, E-GEOD-2685, E-GEOD-15460
Non-decidualised
1
 E-MTAB-680
sarcoma
1
 E-GEOD-2719
brain tumor
1
 E-MTAB-62
cystic fibrosis
1
 E-MTAB-62
55 more value(s).


Compound treatment

studied in E-GEOD-5418, E-GEOD-3284, E-GEOD-412, E-GEOD-7216, E-TABM-127, ... (11 experiments)

Factor Value U/D Experiments
none
3
 E-GEOD-412, E-GEOD-5824, E-GEOD-5418
TTA
1
 E-MEXP-2590
unknown
1
 E-GEOD-7307
bacterial endotoxin
1
1
 E-GEOD-3284
vanadium pentoxide
1
 E-GEOD-5339
chloroguine
1
 E-GEOD-5418
7 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
37 years
1
 E-GEOD-4922
28 years
1
 E-GEOD-4922


BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-2171, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-4667, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-TABM-147, E-GEOD-3013

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578

Genotype
studied in E-MEXP-1996, E-TABM-1029, E-GEOD-2466, E-GEOD-2292, E-TABM-321 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-127, E-GEOD-20540, E-MEXP-1446

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653

Individual
studied in E-MEXP-2069, E-TABM-666, E-GEOD-16363, E-GEOD-21610, E-GEOD-20505, ... (20 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-6434, E-GEOD-1657, E-GEOD-3407

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-1343

Qrt pcr areg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-3697, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Strain or line
studied in E-MEXP-1996

Survival time
studied in E-GEOD-19188

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Processing time: 0.433 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM